Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMDA’s FA Score shows that 0 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMDA’s TA Score shows that 4 TA indicator(s) are bullish.
GMDA (@Biotechnology) experienced а -84.81% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.41%. For the same industry, the average monthly price growth was +5.97%, and the average quarterly price growth was +87.01%.
GMDA is expected to report earnings on May 07, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
GMDA | GWX | |
---|---|---|
RSI ODDS (%) | 1 day ago82% | 1 day ago73% |
Stochastic ODDS (%) | 1 day ago79% | 1 day ago69% |
Momentum ODDS (%) | 1 day ago89% | N/A |
MACD ODDS (%) | 1 day ago89% | N/A |
TrendWeek ODDS (%) | 1 day ago89% | 1 day ago82% |
TrendMonth ODDS (%) | 1 day ago89% | 1 day ago81% |
Advances ODDS (%) | 10 days ago80% | 1 day ago81% |
Declines ODDS (%) | 4 days ago90% | 4 days ago81% |
BollingerBands ODDS (%) | 1 day ago76% | 1 day ago64% |
Aroon ODDS (%) | 1 day ago89% | 1 day ago80% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MDSKX | 23.98 | 0.51 | +2.17% |
iShares Russell 2000 Small-Cap Idx Inv A | |||
PRUIX | 138.02 | 1.20 | +0.88% |
T. Rowe Price Equity Index 500 I | |||
AAIPX | 19.04 | 0.13 | +0.69% |
American Beacon International Eq Inv | |||
FEGKX | 12.93 | 0.02 | +0.15% |
Fidelity Equity Growth K6 | |||
VRESX | 15.33 | N/A | N/A |
Virtus KAR Emerging Markets Small-Cap R6 |